The remaining 29 patients (78.3%) harbored wild-type EGFR. The sites of resected metastatic tumor were the lung (20/37, 54.1%), brain (4/37, 10.8%), pleura (5/37, 13.5%), and others (8/37, 21.6%). Here, EGFR is linked to metastatic neoplasm.